{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glycopyrronium+Bromide&page=2",
    "query": {
      "intervention": "Glycopyrronium Bromide",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glycopyrronium+Bromide&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T00:05:37.537Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06744374",
      "title": "A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "BGF",
          "type": "DRUG"
        },
        {
          "name": "MITT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 22369,
      "start_date": "2024-02-29",
      "completion_date": "2024-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06744374"
    },
    {
      "nct_id": "NCT06112353",
      "title": "Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intestinal Disease"
      ],
      "interventions": [
        {
          "name": "Neostigmine Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2024-04-17",
      "completion_date": "2026-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06112353"
    },
    {
      "nct_id": "NCT03346057",
      "title": "Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Reversal of Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Sugammadex 2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 4 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 16 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine + Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Rocuronium",
          "type": "DRUG"
        },
        {
          "name": "Vecuronium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2017-12-20",
      "completion_date": "2019-09-04",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03346057"
    },
    {
      "nct_id": "NCT03324607",
      "title": "Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "hyperpolarized 129Xe gas MRI",
          "type": "DRUG"
        },
        {
          "name": "Bevespi Aerosphere",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bastiaan Driehuys",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-04-20",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03324607"
    },
    {
      "nct_id": "NCT01697696",
      "title": "Long Term Safety Study of NVA237 vs QAB149 in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "NVA237",
          "type": "DRUG"
        },
        {
          "name": "Long-acting beta 2-agonist (LABA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 511,
      "start_date": "2012-10",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-03-16",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 61,
      "location_summary": "Gulf Shores, Alabama • Mobile, Alabama • Tucson, Arizona + 52 more",
      "locations": [
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01697696"
    },
    {
      "nct_id": "NCT02347761",
      "title": "Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "SUN-101 50 mcg BID eFlow (CS) nebulizer",
          "type": "DRUG"
        },
        {
          "name": "SUN-101 25 mcg BID eFlow (CS) nebulizer",
          "type": "DRUG"
        },
        {
          "name": "Placebo BID eFlow Closed System (CS) nebulizer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sunovion Respiratory Development Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 653,
      "start_date": "2015-02",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2018-03-22",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 44,
      "location_summary": "Anniston, Alabama • Phoenix, Arizona • Tempe, Arizona + 36 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02347761"
    },
    {
      "nct_id": "NCT06351995",
      "title": "Neostigmine and Glycopyrrolate by Iontophoresis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Constipation",
        "Fecal Incontinence",
        "Neurogenic Bowel"
      ],
      "interventions": [
        {
          "name": "Combination of Neostigmine and Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "I-Box by Dynatronics",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "James J. Peters Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 6,
      "start_date": "2020-11-06",
      "completion_date": "2025-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-08",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06351995"
    },
    {
      "nct_id": "NCT05116930",
      "title": "Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Dural Puncture Headache"
      ],
      "interventions": [
        {
          "name": "Neostigmine",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 54 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2021-11-19",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05116930"
    },
    {
      "nct_id": "NCT05830071",
      "title": "A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "CHF5993",
          "type": "DRUG"
        },
        {
          "name": "CHF5259",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400mg",
          "type": "DRUG"
        },
        {
          "name": "CHF5993 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 95,
      "start_date": "2023-03-29",
      "completion_date": "2023-10-13",
      "has_results": false,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05830071"
    },
    {
      "nct_id": "NCT01120691",
      "title": "Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "QVA149",
          "type": "DRUG"
        },
        {
          "name": "NVA237",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol/albuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 2224,
      "start_date": "2010-04",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-12-02",
      "last_synced_at": "2026-09-30T00:05:37.537Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01120691"
    }
  ]
}